REMARKS

Further and favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

Claims 4-14, 17-22, 25, 26, 28, 30, 31, 34, 35, 37 and 39-43 were pending in this application when examined. Non-elected claims 4-14, 19-22, 25, 26, 28, 30, 31, 34, 35 and 39-43 were withdrawn from consideration

Claim 17 has been amended to recite a composition comprising the 2(1H)-pyridinone compound represented by the formula (XVIII) of claim 18, and an inert carrier.

New claim 44 has been added to recite the elected species of compound 3a-32, which can be found on page 165 of the specification.

I. Claim Rejection Under 35 U.S.C. § 102

The Examiner rejects claim 17 under 35 U.S.C. 102(b) as being anticipated by the Vul'fson abstract. As applied to the amended claim, Applicants respectfully traverse the rejection.

Vul'son does not disclose a composition comprising a 2(1H)-pyridinone compound represented by the formula (XVIII) of amended claim 17.

Therefore, claim 17 is not anticipated by the reference.

Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

II. Claim Objection

The Examiner objects to claims 17 and 18 as containing non-elected subject matter.

Claims 17 has been amended to incorporate the 2(1H)-pyridinone compound represented by formula (XVIII) of claim 18. Moreover, amended claim 17 is not anticipated by Vul'fson. As a result, claim 17 has been sufficiently narrowed such that a search of the entire claim can be made without a serious search burden.

Claim 18 is not anticipated by the reference, and should be fully searched. Accordingly, Applicants respectfully request the Examiner to broaden her search to the full scope of claims 17 and 18

U.S. Serial No. 10/572,705 Attorney Docket No. 2006_0367A August 6, 2010

III. Information Disclosure Statement

Applicants submit herewith an Information Disclosure Statement. Applicants respectfully request consideration of the references cited on the attached Form PTO/SB/08.

IV. New Claim

The cited reference does not disclose the compound of claim 44. Accordingly, prompt examination and allowance of claim 44 are respectfully requested.

V. Conclusion

For these reasons, Applicants take the position that the presently claimed invention is clearly patentable over the applied reference.

Therefore, in view of the foregoing amendments and remarks, it is submitted that the objection and rejection set forth by the Examiner has been overcome, and that the application is in condition for allowance. Such allowance is solicited.

Respectfully submitted,

Yoshitaka TOMIGAHARA et al.

/Andrew B. Digitally signed by //Indrew B. Freistein, On/NLP. ou-/NLP. email-afreistein/conenderoth.

By Freistein/

Andrew B. Freistein Registration No. 52,917 Attorney for Applicants

ABF/emj Washington, D.C. 20005-1503 Telephone (202) 721-8200 Facsimile (202) 721-8250 August 6, 2010